Search published articles


Showing 23 results for Multiple Sclerosis
Evaluation of the relationship between axon injury and clinical symptoms in patients with multiple sclerosis using diffusion tensor MRI imaging
Milad Jalilian, Iraj Abedi, Mohammadreza Sharifi,
Volume 80, Issue 2 (5-2022)
Abstract

Background: Magnetic resonance imaging (MRI) is a non-invasive imaging technology that shows detailed anatomical and pathological images. It is often used for disease detection, diagnosis, and treatment monitoring, in particular with neurodegenerative diseases, such as Multiple sclerosis (MS), Alzheimer's and amyotrophic lateral sclerosis. However, conventional MRI provides only qualitative information and cannot distinguish between myelin and axon destruction. One of the new methods in early detection for axonal injury is the DTI sequence, which can be used to observe and quantify the various dimensions of these plaques, including the direction of diffusion and average diffusion. In other words, in DTI, quantitative data from the image helps to estimate the physiological and pathophysiological information of plaques in the brain. This study aimed to investigate the relationship between DTI parameters including FA, MD, RD, AD, axon injury and severity of clinical symptoms in patients with MS.
Methods: This is a cross-sectional control case study that was performed in Isfahan Milad Hospital from December 2020 to August 2021. DTI imaging was performed on 41 patients with MS and 41 normal individuals, and DTI indices including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) in different areas of the brain were evaluated. A visual analog scale (VAS) was used to assess the severity of clinical symptoms in patients. The relationship between DTI indices and the severity of clinical symptoms and axon injury was analyzed by the Kolmogorov-Smirnov test.

Results: Correlation analysis showed that there is a significant correlation between DTI sequence parameters and the VAS visual analog scale (P˂0.05) and according to the positive values of the correlation coefficient, there was a positive and significant relationship between VAS and the mentioned parameters and with increasing parameters. The DTI sequence of the Visual Analog Scale (VAS) was significantly increased.

Conclusion: Indicators obtained from the DTI sequence can be used in the prognosis of the disease and the estimation of the severity of clinical symptoms during the patients' involvement.


Evaluation of the one-year effectiveness and side effects of rituximab in patients with multiple sclerosis in Kermanshah
Nazanin Razazian, Mansour Rezaei, Poona Ahmadi, Negin Fakhri,
Volume 80, Issue 4 (7-2022)
Abstract
Background: Multiple sclerosis (MS) is an inflammatory disease affecting the central nervous system. Rituximab (Zytux) is a type of monoclonal antibody against B cells with CD20 antigen that reduces B cells. The present study examined the one-year effectiveness and side effects of Rituximab.
Methods: This quasi-experimental clinical trial was conducted from September 2018 to September 2019 in Imam Reza Hospital in Kermanshah. 44 eligible patients were selected by the available sampling method and entered the study after evaluation in terms of inclusion and exclusion criteria. Patients were treated with rituximab for one year. At the beginning of the study and at the end of the year, the disability score based on the Expanded Disability Status Scale (EDSS) and active lesions based on MRI for patients were evaluated. Also, the patients were followed up in terms of relapse and medication side effects throughout the year. This study was performed with the support of Kermanshah University of Medical Sciences. Informed consent was obtained from all participants. The data were analyzed by SPSS-25 software.
Results: 44 patients with MS including 29 (65.9%) female and 15 (34.1%) male were studied. 22 patients had RRMS and 22 patients had progressive-relapsing MS (PRMS). In patients with RRMS, the EDSS score at the end of the study was significantly reduced compared to the beginning of the study (P=0.010) but in PRMS patients EDSS was increased but this increase was not significant (P=0.148). In both RRMS and PRMS patients, the number of MRI lesions at the end of the study was lower than the beginning of the study and this decrease was not significant (P>0.05). More Immediate side effects occurred in RRMS patients (13.6% vs. 4.5%) and more delayed side effects were observed in PRMS patients (54.5% vs. 36.3%).
Conclusion: rituximab caused a greater reduction in EDSS in the treatment of RRMS than PRMS and its use had few side effects.

Outcomes of AstraZeneca vaccine for relapse and Covid-19 infection in people with multiple sclerosis
Nazanin Razazian, Mohammad-Ali Sahraian, Sharareh Eskandarieh, Nooshin Jafari, Mansour Rezaei, Negin Fakhri,
Volume 80, Issue 6 (9-2022)
Abstract
Background: People with chronic diseases of the immune system, such as multiple sclerosis (MS), are at risk for Covid-19 disease. However, more research is needed with long-term follow-up. The aim of the study was to follow up people with MS (PwMS) for up to three months after AstraZeneca vaccination for the recurrence of MS and Covid-19 infection.
Methods: This study was a case study (descriptive-analytical) of follow-up type. The study population was PwMS over 18 years of age in Kermanshah province who received both doses of the AstraZeneca vaccine. This study was conducted from August to November 2021. Sampling was done with existing methods based on the National MS Registry of Iran (NMSRI). Demographic information of patients was extracted from NMSRI. A researcher-made form was used to collect information by telephone three months after vaccination about clinical characteristics, Covid-19 infection, and recurrence of MS. Data were analyzed using SPSS-25 software.
Results: Study participants were 40 MS patients with a mean (SD) age of 39.27 (8.8) years, including 32 (80.0%) women. A mean of 9.39 (4.6) years had passed since The patients were diagnosed with MS, and 29 (76.4%) had RR type MS. Four patients (10%) relapsed between the second dose and three months later, of whom two (50%) had sensory symptoms, one (25%) had optic nerve involvement, and one (25%) had motor symptoms and pyramidal pathway involvement. The symptoms of Covid-19 were mild in three patients (10%), while severe symptoms developed in one patient (10%) who received rituximab. Among the patients, no cases of thrombosis were observed. Infusion therapy, a leg fracture, and kidney stones were the only hospitalized cases.
Conclusion: Covid-19 and MS relapse prevalence did not differ significantly in the three months before and after vaccination. There is a need for further studies with a longer follow-up period.

Page 2 from 2     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb